ClinicalTrials.gg
Active, not recruitingNCT05377034STRATUMUpdated Oct 20, 2026

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

A Phase 2 interventional study of SIRT-Y90 with Atezolizumab + Bevacizumab and SIRT-Y90 with Placebo (IV) in Locally Advanced Hepatocellular Carcinoma, sponsored by National Cancer Centre, Singapore. Active, not recruiting at 14 sites in 4 countries. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by National Cancer Centre, Singapore · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Updated Oct 20, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore — 4 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · National Cancer Centre, Singapore.

Enrollment
Largest of 11
119 · median 40
Started
2022
the only one that year
Phase 2
6 of 17
2 open now
Registered
13th of 17
by date

Among the 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 2, and was the 13th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

4 of the 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore, or all of them as a file.
02

Study summary

This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90 followed by placebo [control arm] in patients with locally advanced Hepatocellular Carcinoma (HCC).

Read the detailed description

This study will enroll 100 patients randomized in a 1:1 allocation ratio (50 in each arm) to one of the two arms.

  • Study arm: SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab
  • Control arm: SIRT-Y90 + placebos (IV)

The patients will be recruited from up to 15 sites from the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (subjected to feasibility studies and ethics approval). Proposed sites are in Singapore, China, South Korea, and Taiwan.

03

Conditions studied

  • Locally Advanced Hepatocellular Carcinoma

Keywords

  • SIRT-Y90
  • Atezolizumab plus Bevacizumab
  • Hepatocellular Carcinoma
  • SIR-Sphere
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must fulfill all of the following criteria to be eligible for this study:

  1. Unequivocal diagnosis of HCC (AASLD 2010 diagnostic criteria or histology) that is locally advanced without extra-hepatic but with significant tumor burden, i.e.,

    • Tumor confined to the liver that is beyond the up-to-7 criteria, and/or
    • Tumor with vascular invasion VP 1-3 and/or Vv 1-2 (at the discretion of site investigator) Both local and central assessments are required at screening, prior to any study treatment. Sites are required to send all CT/MRI images for central imaging review. The central assessment result will be made known to sites and will take precedence in determining a patient's study eligibility in case of a discrepancy between local and central review.
  2. Aged 21 years old and above of either gender.
  3. Patient eligible for SIRT-Y90 treatment after assessment with macro-aggregated albumin labeled with technetium-99 (Tc-99m MAA) scan on SPECT/CT or planar imaging with all of the following criteria prior to each SIRT-Y90 treatment:

    • Lung shunting \<20% on SPECT/CT or planar imaging
    • Lung dose limit of \<25Gy for single treatment or \<30Gy for cumulative treatment (second delivery within 4-6 weeks)
  4. No prior radiation to the liver.
  5. No prior systemic or neoadjuvant therapy for HCC.
  6. , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with spiral CT scan or MRI.
  7. Negative test at screening, with the following exception - patients with a positive HIV test at screening are eligible provided they fulfil all of the following criteria:

    • Are stable on anti-retroviral therapy
    • Have a ≥ 200/μL
    • Have an undetectable viral load
  8. Documented virology status of hepatitis, as confirmed by screening virus (HBV) and virus (HCV) tests.
  9. Patients with active HBV: HBV DNA \<3000 IU/mL, initiation of anti-HBV treatment at least 14 days prior to randomization, and willingness to continue anti-HBV treatment during the study (per local standard of care; e.g., entecavir).

    For patients with HBV DNA ≥ 500 IU/mL during screening, anti-HBV treatment will be initiated and HBV DNA levels will be re-assessed prior to randomization.

  10. performance status 0 - 1.
  11. A (up to 6 points).
  12. Adequate hematological, renal, and hepatic function as follows:

    • Lymphocyte count ≥ 0.5 x 10**9/L (500/μL)
    • ≥75,000/μL without transfusion
    • >9.5 g/dL (Patients may be transfused to meet this criterion.)
    • Serum ≤ 3 x
    • For patients not receiving therapeutic anticoagulation: and aPTT ≤ 2.0 x ULN
    • ALP ≤5×institutional upper limit of normal
    • and ALT ≤5×institutional upper limit of normal
    • Albumin ≥2.8 g/dL
    • Serum creatinine ≤ 1.5 x ULN or ≥ 30 mL/min (calculated using the Cockcroft-Gault formula)
    • ≥1.5×10**9/L without granulocyte colony-stimulating factor support
    • Urine dipstick for proteinuria \<2+ at screening

      • Patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \<1g of protein in 24 hours
  13. of at least 3 months without any active treatment.
  14. Suitable for protocol treatment as determined by clinical assessment undertaken by the site investigator.
  15. Performance of an esophagogastroduodenoscopy (EGD) within 6 months prior to randomization as part of pre-procedure work-up or during screening, and assessment and complete treatment of varices of all sizes per local standard of care prior to randomization.

    Patients with varices should be re-assessed prior to randomization to ensure complete treatment of varices of all sizes per local standard of care.

  16. Willing, able and mentally competent to provide written prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the patient's routine care.
  17. Female patients must be either or, if premenopausal, must have a negative pregnancy test and agree to use two forms of if sexually active during the treatment period, for at least 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab.
  18. Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner, they must be using an acceptable form of contraception during the treatment period and for 6 months after the last dose of bevacizumab.

Exclusion criteria

Exclusion Criteria:

The following criteria should be checked. If ANY apply, the patient must not be included in the study:

  1. Patient not eligible for SIRT-Y90 treatment after assessment with macro-aggregated albumin labeled with technetium-99 (MAA) scan on SPECT/CT or planar imaging.
  2. Patients who have SAE > grade 3 within 4 weeks after receiving SIRT-Y90. For patients who experience SAE > grade 3 after receiving SIRT-Y90 (1st or 2nd administration), the duration between the SIRT-Y90 dose and randomization and/or 1st and 2nd SIRT-Y90 dose (for two-staged delivery) may be extended by an additional 4 weeks to re-assess the patient's eligibility.
  3. Patients who have had >2 administrations of hepatic artery directed therapy.
  4. Patients who have had hepatic artery directed therapy done \<4 weeks prior to date of ICF signing.
  5. Patients who have had systemic or neoadjuvant therapy for HCC.
  6. Prior hepatic radiation therapy for HCC or other .
  7. Patient who has received any immunotherapy (including interferon-alfa, peginterferon alfa-2a, peginterferon alfa-2b, thymosin-α1, etc.) within 30 days prior to randomization, is currently receiving immunotherapy or is planned to start immunotherapy during the study (e.g., for the management of active CHB or CHC according to local guidelines).
  8. Has evidence that \<30% of the total liver volume is disease-free.
  9. Currently receiving any other agents for the treatment of their cancer.
  10. Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination.
  11. Untreated or incompletely treated esophageal and/or gastric varices prior to randomization.
  12. Presence of tumor thrombus in the main trunk of the portal vein or a portal vein branch contralateral to the primarily involved lobe (or both) i.e. beyond VP3 and/or tumor thrombus in the inferior vena cava or right atrium i.e. beyond Vv2.
  13. Any disease i.e. lymph node ≥15 mm in short axis or distant metastasis.
  14. Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.
  15. Presence of clinical signs of due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events.
  16. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  17. Inadequately controlled arterial hypertension (defined as systolic blood pressure [BP]>150 mmHg and/or diastolic BP >100 mmHg), based on an average of at least three BP readings on separate occasions.

    • Anti-hypertensive therapy to achieve these parameters is allowed.
  18. Any of the following to angiography and selective visceral catheterization:

    • Bleeding diathesis, not correctable by the standard forms of therapy.
    • Severe peripheral vascular disease that would preclude arterial catheterization.
  19. Significant cardiovascular disease (such as cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to randomization), unstable arrhythmia, or unstable angina.
  20. History of congenital long syndrome or corrected QT interval > 500 ms (calculated with use of the Fridericia method) at screening
  21. History of uncorrectable electrolyte disorder affecting serum levels of potassium, calcium, or magnesium
  22. Current or recent use (within 10 days prior to angiogram) of aspirin (>325 mg/day) or current or recent treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol.

    • Use of dipyridamole, ticlopidine, clopidogrel, and cilostazol is allowed for patients who do not have any active bleeding for the past 6 months after review with attending physician.
  23. Current or recent (within 10 days prior to angiogram) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose.

    • Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an \<1.5× and aPTT is within normal limits (according to institutional standards) within 14 days prior to Day 1 of Cycle 1.
    • Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.
  24. History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIRT-Y90 or atezolizumab or bevacizumab.
  25. The patient has active or history of disease or immune deficiency such as, but not limited to, multiple sclerosis, systemic lupus erythematosus, and inflammatory bowel disease, with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

      • Rash must cover \< 10% of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months prior to screening.
  26. The patient requires concomitant treatment with any or immunostimulant agent, or with systemic corticosteroids prescribed for chronic treatment (more than 7 consecutive days).
  27. Inability or unwillingness to understand or sign a written document.
  28. Female patients who are pregnant or currently breastfeeding.
  29. Current enrolment in any other investigational therapeutic drug or device study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Study Arm

    SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab

    Combination Product: SIRT-Y90 with Atezolizumab + Bevacizumab

  • Experimental
    Control Arm

    SIRT-Y90 + placebos (IV)

    Combination Product: SIRT-Y90 with Placebo (IV)

Interventions

  • Combination productSIRT-Y90 with Atezolizumab + Bevacizumab

    Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.

  • Combination productSIRT-Y90 with Placebo (IV)

    Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (BORR) at 9 months post-randomization.

    The number of patients whose Best Overall Response (BOR) at 9 months post-randomization is a partial response or complete response per RECIST v1.1 and mRECIST, divided by the total number of patients in the analysis population.

    Time frame: 9 months post-randomization.

Secondary outcomes

  1. Best Overall Response Rate (BORR) at 12-months and 18-months post-randomization.

    The number of patients whose Best Overall Response (BOR) at 12 and 18 months post-randomization is a partial response or complete response per RECIST v1.1 and mRECIST, divided by the total number of patients in the analysis population.

    Time frame: 12 months and 18 months post-randomization.

  2. Sustained response rates at 9, 12 and 18 months.

    The number of patients whose BOR at time t (t = 9, 12 and 18 months) is a partial response or complete response confirmed on a subsequent visit by CT scan, divided by the total number of patients in the analysis population.

    Time frame: 9,12 and 18 months post-randomization.

  3. Disease control rates at 9, 12 and 18 months.

    The number of patients whose BOR at time t (t = 9, 12 and 18 months) is a partial response, complete response, or stable disease per RECIST v1.1 and mRECIST, divided by the total number of patients in the analysis population.

    Time frame: 9,12 and 18 months post-randomization.

  4. Time to response.

    The time between randomization and the date of first partial response or complete response. For those who have no partial response or complete response by the time of analysis will be censored on the date of last evaluable tumor assessment on or before the time of analysis or the end of study treatment, whichever is earlier.

    Time frame: Up to 19 months post-randomization.

  5. Duration of response (DOR).

    DOR is the time from the date of first partial response or complete response to date of tumor progression or death from any cause, whichever is earlier. For those who are alive and have not experienced disease progression by the time of analysis will be censored on the date of last evaluable tumor assessment on or before the time of analysis or the end of study treatment, whichever is earlier.

    Time frame: Up to 19 months post-randomization.

  6. Time to disease progression.

    The time between randomization and the date of tumor progression at any site in the body or death due to HCC. For those who remain alive or died due to other reasons or have not experienced disease progression, time to disease progression will be censored on the date of last evaluable tumor assessment on or before the time of analysis or the end of study treatment, whichever is earlier.

    Time frame: Up to 19 months post-randomization.

  7. Progression-free survival (PFS).

    The time from randomization to the date of tumor progression at any site in the body or death from any cause, whichever is earlier. For those who remain alive and have not progressed, PFS will be censored on the date of the last evaluable tumor assessment on or before the time of analysis or the end of study treatment, whichever is earlier. Progression-free survival rates will also be calculated at time t (t = 12 and 18 months).

    Time frame: Up to 19 months post-randomization.

  8. Overall survival (OS).

    The time from randomization to death from any cause. Patients who are alive will be censored at the last date the patient was known to be alive on or before the time of analysis. Overall survival rates will also be calculated at time t (t = 12 and 18 months).

    Time frame: 12 and 18 months post-randomization.

  9. EQ-5D-5L utility index at 12 and 18 months.

    The EQ-5D-5L utility index will be calculated using the EQ-5D-5L value set for the recruiting site country (Singapore, China, South Korea, and Taiwan) based on EQ-5D-5L assessment at time t (t = 12 and 18 months). Currently, there is no value set available for Singapore. However, if it will not be available by the time of the analysis, another suitable country's value set will be used. The EQ-VAS will also be used as an additional measure.

    Time frame: 12 and 18 months post-randomization.

  10. FACT-Hep scores at 12 and 18 months.

    The FACT-Hep total score along with subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, hepatobiliary cancer, trial outcome index, FACT-G total score) will be calculated using the FACT-Hep (version 4) scoring guideline based on FACT-Fep assessment at time t (t = 12 and 18 months).

    Time frame: 12 and 18 months post-randomization.

  11. Quality-adjusted life years at 18 months.

    The quality-adjusted life-years (QALYs) will be calculated as the area under the EQ-5D-5L index during the 18 months.

    Time frame: 18 months post-randomization.

Other outcomes

  1. SIRT-Y90 post-treatment dosimetry.

    Voxel-level mean tumor absorbed dose (Dmean) and mean biological effective dose (BEDmean) for SIRT-Y90 will be calculated using CT images using local deposition method. In addition, administered activity and mean absorbed dose to treated liver volume (including both tumoral and non-tumoral tissue) will be used as dosimetry parameters. Dose response evaluation will be attempted based on the information obtained and follow-up anatomical evaluation. The impact of tumour absorbed dose on BORR, tumour response as assessed by RECIST v1.1 and mRECIST and outcomes of patients receiving SIRT-Y90 (3, 6, 12 and 18 months) will be assessed.

    Time frame: 4-week SIRT pre-randomization; 3, 6, 12 and 18 months post-randomization.

  2. Hepatic progression-free survival (HPFS).

    Hepatic progression-free survival (HPFS) is defined as the time from randomization and the date of tumor progression in liver or death from any cause, whichever is earlier. For those who remain alive and have not progressed in the liver, HPFS will be censored on the date of the last evaluable tumor assessment on or before the time of analysis or end of study treatment, whichever is earlier.

    Time frame: Up to 19 months post-randomization.

  3. Tumor resectability rates at 12 and 18 months.

    Tumor resectability rate at time t (t = 12 and 18 months) is defined as the number of patients undergone surgical resection for the target lesions of HCC by time t, divided by the total number of patients in the analysis population.

    Time frame: 12 and 18 months post-randomization.

  4. Impact of Albumin-Bilirubin (ALBI) grade on the overall survival and progression-free survival outcomes of HCC patients undergoing SIRT-Y90.

    The ALBI (Albumin-Bilirubin) score is calculated based on serum albumin and bilirubin levels and values are classified into three ALBI grades: Grade 1, Grade 2 and Grade 3, where Grade 1 indicates a better outcome. In this trial, the ALBI grade at screening will be correlated to information obtained during treatment and follow up visits such as clinical outcomes like mortality, grade 3 or 4 adverse events and/or radiological responses as measured by RECIST v1.1 and mRECIST.

    Time frame: Up to 19 months post-randomization.

  5. Occurrence of adverse events and adverse events related to study treatment.

    Occurrence of adverse events and adverse events related to study treatment up to 30 days post last study treatment dose, including abnormal hematological and biochemical parameters.

    Time frame: Up to 19 months post-randomization.

  6. Occurrence of ≥3 grade adverse events (graded with NCI CTCAE v5.0).

    Occurrence of ≥3 grade adverse events (graded with NCI CTCAE v5.0) up to 30 days post last study treatment dose, including abnormal hematological and biochemical parameters.

    Time frame: Up to 19 months post-randomization.

  7. Occurrence of adverse events of special interest.

    Occurrence of adverse events of special interest up to 90 days post last study treatment dose, including abnormal hematological and biochemical parameters.

    Time frame: Up to 21 months post-randomization.

  8. Occurrence of adverse events leading to study treatment discontinuation or interruption.

    Occurrence of adverse events leading to study treatment discontinuation or interruption.

    Time frame: Up to 18 months post-randomization.

  9. Occurrence of serious adverse events after initiation of study treatment until 90 days post last study treatment dose.

    Occurrence of serious adverse events after initiation of study treatment until 90 days post last study treatment dose.

    Time frame: Up to 21 months post-randomization.

  10. Occurrence of adverse events leading to death.

    Occurrence of adverse events leading to death.

    Time frame: Up to 21 months post-randomization.

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Feb 2027, 51 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 51 months is close to that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2026 → Feb 2027 and completion Jan 2028 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2022
First posted
May 17, 2022
StartActual
Oct 26, 2022
Primary completionEst.
Feb 15, 2027was Jul 2026
CompletionEst.
May 6, 2028was Jan 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Primary completion
Jul 25, 2026→Feb 15, 2027
Oct 20, 2026
Study completion
Jan 31, 2028→May 6, 2028
Oct 20, 2026
Enrollment
100 (estimated)→119 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 25, 2026→Feb 15, 2027
    Study completion Jan 31, 2028→May 6, 2028
    Enrollment 100 (estimated)→119 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05377034
Collaborators
Hoffmann-La Roche, Sirtex Medical, Singapore Clinical Research Institute
Responsible party
Sponsor
First posted
May 17, 2022
Start date
Oct 26, 2022
Primary completion
Feb 15, 2027 (estimated)
Completion
May 6, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Pierce CHOW, MD, PhD
principal investigator · National Cancer Centre, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion